Lantern Pharma
LTRN
23 hedge funds and large institutions have $5.4M invested in Lantern Pharma in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.
2,050% more call options, than puts
Call options by funds: $43K | Put options by funds: $2K
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
3.45% less ownership
Funds ownership: 13.27% → 9.82% (-3.5%)
12% less funds holding
Funds holding: 26 → 23 (-3)
21% less capital invested
Capital invested by funds: $6.84M → $5.4M (-$1.45M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$75.8K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$60.1K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$50.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$32.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$1.72M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
-$150K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$70K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19K |
| 5 |
WWM
Wolff Wiese Magana
Carslbad,
California
|
-$16.8K |
LTRN Hedge Fund Activity: Q4 2022 in Review
23 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q4 2022, worth a combined $5.4M — down 21% from $6.84M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LTRN and 3 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Jane Street, opening a new position worth an estimated $75.8K. The largest seller was Sanders Morris Harris, exiting entirely with an estimated $1.72M sold.
- 23 institutional investors held Lantern Pharma (LTRN) as of Q4 2022, down from 26 in Q3 2022.
- Funds reported $5.4M of Lantern Pharma stock for Q4 2022, down 21% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q4 2022 and 6 closed out, a net change of -3 holders.
- The largest Lantern Pharma buyer in Q4 2022 was Jane Street, an estimated $75.8K added.
- The largest Lantern Pharma seller in Q4 2022 was Sanders Morris Harris, an estimated $1.72M sold.
Based on aggregated 13F filings for Q4 2022.